HU185223B - Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen - Google Patents
Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen Download PDFInfo
- Publication number
- HU185223B HU185223B HU802661A HU266180A HU185223B HU 185223 B HU185223 B HU 185223B HU 802661 A HU802661 A HU 802661A HU 266180 A HU266180 A HU 266180A HU 185223 B HU185223 B HU 185223B
- Authority
- HU
- Hungary
- Prior art keywords
- plasminogen
- streptokinase
- benzoyl
- derivative
- blocking
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title claims abstract description 35
- 108010051456 Plasminogen Proteins 0.000 title claims abstract description 35
- 230000002255 enzymatic effect Effects 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229960005202 streptokinase Drugs 0.000 claims abstract description 42
- 108010023197 Streptokinase Proteins 0.000 claims abstract description 41
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 229940088598 enzyme Drugs 0.000 claims abstract description 19
- 230000003197 catalytic effect Effects 0.000 claims abstract description 18
- 230000007062 hydrolysis Effects 0.000 claims abstract description 16
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 16
- 230000003480 fibrinolytic effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 18
- -1 phenyl ester Chemical class 0.000 claims description 18
- 230000000903 blocking effect Effects 0.000 claims description 15
- 239000002981 blocking agent Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 125000005425 toluyl group Chemical group 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- SXTSBZBQQRIYCU-UHFFFAOYSA-N 4-guanidinobenzoic acid Chemical group NC(=N)NC1=CC=C(C(O)=O)C=C1 SXTSBZBQQRIYCU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 239000012736 aqueous medium Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 108010056373 SK potentiator Proteins 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- JWKAIXSLWGLVPE-UHFFFAOYSA-N (4-carbamimidoylphenyl) 4-methoxybenzoate Chemical compound C1=CC(OC)=CC=C1C(=O)OC1=CC=C(C(N)=N)C=C1 JWKAIXSLWGLVPE-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 108010087750 lysyl-plasminogen Proteins 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 229940127126 plasminogen activator Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000103 thrombolytic agent Drugs 0.000 description 3
- OPVAJFQBSDUNQA-UHFFFAOYSA-N 3,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1C OPVAJFQBSDUNQA-UHFFFAOYSA-N 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ICWQQIIQYKWDKV-UHFFFAOYSA-N (4-carbamimidoylphenyl) 2,4-dimethoxybenzoate Chemical compound COC1=CC(OC)=CC=C1C(=O)OC1=CC=C(C(N)=N)C=C1 ICWQQIIQYKWDKV-UHFFFAOYSA-N 0.000 description 1
- XLFFXYYAMVYCSQ-UHFFFAOYSA-N (4-carbamimidoylphenyl) 4-butylbenzoate Chemical compound C1=CC(CCCC)=CC=C1C(=O)OC1=CC=C(C(N)=N)C=C1 XLFFXYYAMVYCSQ-UHFFFAOYSA-N 0.000 description 1
- OCAHKLLJCGKWCH-UHFFFAOYSA-N (4-carbamimidoylphenyl) 4-fluorobenzoate Chemical compound C1=CC(C(=N)N)=CC=C1OC(=O)C1=CC=C(F)C=C1 OCAHKLLJCGKWCH-UHFFFAOYSA-N 0.000 description 1
- FHXLAICKMGGSKP-UHFFFAOYSA-N (4-carbamimidoylphenyl) 4-methoxy-3-methylbenzoate Chemical compound C1=C(C)C(OC)=CC=C1C(=O)OC1=CC=C(C(N)=N)C=C1 FHXLAICKMGGSKP-UHFFFAOYSA-N 0.000 description 1
- FXWXBLXPGAZOHE-UHFFFAOYSA-N (4-carbamimidoylphenyl) benzoate Chemical compound C1=CC(C(=N)N)=CC=C1OC(=O)C1=CC=CC=C1 FXWXBLXPGAZOHE-UHFFFAOYSA-N 0.000 description 1
- CFOQGBUQTOGYKI-UHFFFAOYSA-N (4-nitrophenyl) 4-(diaminomethylideneamino)benzoate Chemical group C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 CFOQGBUQTOGYKI-UHFFFAOYSA-N 0.000 description 1
- GMKZBFFLCONHDE-UHFFFAOYSA-N (4-nitrophenyl) benzoate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)C1=CC=CC=C1 GMKZBFFLCONHDE-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical group CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VRJWMZFTJMHQJF-UHFFFAOYSA-N 4-carbamimidoyl-2-methoxy-3-phenylbenzoic acid Chemical compound COC1=C(C=CC(=C1C2=CC=CC=C2)C(=N)N)C(=O)O VRJWMZFTJMHQJF-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YYXYBWIDIWTCGS-UHFFFAOYSA-N chembl363685 Chemical compound NC(=N)C1=CC=C(O)C=C1 YYXYBWIDIWTCGS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7938279 | 1979-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU185223B true HU185223B (en) | 1984-12-28 |
Family
ID=10508982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU802661A HU185223B (en) | 1979-11-05 | 1980-11-05 | Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4808405A (show.php) |
| EP (1) | EP0028489B1 (show.php) |
| JP (1) | JPS5678590A (show.php) |
| AR (1) | AR224786A1 (show.php) |
| CA (1) | CA1174621A (show.php) |
| CS (2) | CS391991A3 (show.php) |
| DE (1) | DE3065190D1 (show.php) |
| DK (1) | DK158994C (show.php) |
| ES (1) | ES496586A0 (show.php) |
| GR (1) | GR72121B (show.php) |
| HK (1) | HK65886A (show.php) |
| HU (1) | HU185223B (show.php) |
| IE (1) | IE50174B1 (show.php) |
| IL (1) | IL61408A (show.php) |
| NL (1) | NL930029I2 (show.php) |
| NO (1) | NO163867C (show.php) |
| NZ (1) | NZ195469A (show.php) |
| ZA (1) | ZA806641B (show.php) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3361610D1 (en) * | 1982-04-07 | 1986-02-06 | Beecham Group Plc | Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them |
| EP0125269A1 (en) * | 1982-11-11 | 1984-11-21 | Beecham Group Plc | Pharmaceutically active compounds |
| GB8400653D0 (en) * | 1984-01-11 | 1984-02-15 | Beecham Group Plc | Conjugates |
| GB8430253D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US5231006A (en) * | 1986-10-16 | 1993-07-27 | Behringwerke Aktiengesellschaft | Method for the determination of plasminogen |
| US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| JPH0296536A (ja) * | 1988-09-29 | 1990-04-09 | Green Cross Corp:The | プラスミノゲン乾燥製剤 |
| AU647391B2 (en) * | 1989-05-01 | 1994-03-24 | University Of Notre Dame Du Lac, The | Methods and materials for expression of human plasminogen in a eukaryotic cell system |
| EP0397366A1 (en) * | 1989-05-09 | 1990-11-14 | The Board Of Regents Of The University Of Oklahoma | Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same |
| DE69025934T2 (de) * | 1989-05-17 | 1996-09-19 | Res Corp Technologies Inc | Verfahren und zusammensetzung zur thrombosebehandlung beim säugetier |
| CA2027936C (en) | 1989-10-23 | 2001-07-24 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| US5190756A (en) * | 1989-12-01 | 1993-03-02 | Genentech, Inc. | Methods and materials for expression of human plasminogen variant |
| US5087572A (en) * | 1989-12-01 | 1992-02-11 | Genentech, Inc. | Dna encoding human plasminogen modified at the cleavage site |
| GB8928163D0 (en) * | 1989-12-13 | 1990-02-14 | Beecham Group Plc | Novel treatment |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| US5187069A (en) * | 1990-08-06 | 1993-02-16 | Henry Ford Health System | Active site labelling of plasminogen |
| AU1873092A (en) * | 1991-04-09 | 1992-11-17 | Brigham And Women's Hospital | Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques |
| US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| DE4411143C2 (de) * | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| US6004955A (en) * | 1996-08-15 | 1999-12-21 | Dupont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists |
| JP2002507968A (ja) | 1997-06-19 | 2002-03-12 | デュポン ファーマシューティカルズ カンパニー | 中性のＰ１特異性基を有するＸａ因子阻害剤 |
| EP1203026A4 (en) * | 1999-07-29 | 2005-03-16 | Dyax Corp | BINDING CENTERS FOR FIBRIN |
| US6388073B1 (en) | 2000-07-26 | 2002-05-14 | Shire Us Inc. | Method for the manufacture of anagrelide |
| KR20010000669A (ko) * | 2000-10-12 | 2001-01-05 | 김기환 | 스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제 |
| US6984373B2 (en) * | 2000-12-23 | 2006-01-10 | Dyax Corp. | Fibrin binding moieties useful as imaging agents |
| BRPI0212726B8 (pt) | 2001-09-21 | 2021-05-25 | Bristol Myers Squibb Co | compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7700608B2 (en) * | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
| US20060030574A1 (en) * | 2004-08-04 | 2006-02-09 | Shire Holdings Ag | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
| US7459564B2 (en) | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
| MX2007008434A (es) | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
| US7714002B2 (en) | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| ES2352796T3 (es) | 2005-06-27 | 2011-02-23 | Bristol-Myers Squibb Company | Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas. |
| AU2006261828A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7816382B2 (en) | 2005-06-27 | 2010-10-19 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition |
| JP2009539873A (ja) | 2006-06-08 | 2009-11-19 | ブリストル−マイヤーズ スクイブ カンパニー | 抗凝固剤として有用な第ＶＩＩａ因子インヒビターとしての２−アミノカルボニルフェニルアミノ−２−フェニルアセトアミド類 |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| US7910597B2 (en) * | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
| EP2102189B1 (en) | 2006-12-15 | 2015-07-29 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| AU2008266228A1 (en) | 2007-06-13 | 2008-12-24 | Bristol-Myers Squibb Company | Dipeptide analogs as coagulation factor inhibitors |
| US20090130017A1 (en) * | 2007-11-19 | 2009-05-21 | Searete Llc | Targeted short-lived drug delivery |
| PE20091972A1 (es) | 2008-05-19 | 2010-01-15 | Schering Corp | Compuestos heterociclicos como inhibidores del factor ixa |
| SMT202000093T1 (it) | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| ES2822130T3 (es) | 2010-02-11 | 2021-04-29 | Bristol Myers Squibb Co | Macrociclos como inhibidores del factor XIa |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
| EA023649B1 (ru) | 2011-10-14 | 2016-06-30 | Бристол-Майерс Сквибб Кампани | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa |
| IN2014CN02806A (show.php) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| MD20140044A2 (ro) | 2011-11-11 | 2014-08-31 | Pfizer Inc. | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare |
| HK1206735A1 (en) | 2012-04-06 | 2016-01-15 | 辉瑞公司 | Diacylglycerol acyltransferase 2 inhibitors |
| CA2880898A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| HUE032622T2 (en) | 2012-08-03 | 2017-10-30 | Bristol Myers Squibb Co | Dihydropyridone p1 as factor xia inhibitors |
| US9738655B2 (en) | 2013-03-25 | 2017-08-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors |
| ES2665153T3 (es) | 2013-10-09 | 2018-04-24 | Pfizer Inc. | Antagonistas del receptor EP3 de prostaglandina |
| NO2760821T3 (show.php) | 2014-01-31 | 2018-03-10 | ||
| TWI859674B (zh) | 2014-01-31 | 2024-10-21 | 美商必治妥美雅史谷比公司 | 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物 |
| TR201809388T4 (tr) | 2014-03-17 | 2018-07-23 | Pfizer | Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri. |
| EP3536685B1 (en) | 2014-04-04 | 2022-02-16 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| NO2721243T3 (show.php) | 2014-10-01 | 2018-10-20 | ||
| CU20170134A7 (es) | 2015-05-05 | 2017-12-08 | Pfizer | 2-tiopirimidinonas |
| PL3310784T3 (pl) | 2015-06-17 | 2021-03-08 | Pfizer Inc. | Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| EP3868753B1 (en) | 2015-07-29 | 2022-12-21 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group |
| WO2017023992A1 (en) | 2015-08-05 | 2017-02-09 | Bristol-Myers Squibb Company | Novel substituted glycine derived fxia inhibitors |
| LT3341367T (lt) | 2015-08-27 | 2021-04-26 | Pfizer Inc. | Biciklinis sulietas heteroarilas arba arilo junginiai kaip irak4 moduliatoriai |
| WO2017151746A1 (en) | 2016-03-02 | 2017-09-08 | Bristol-Myers Squibb Company | Diamide macrocycles having factor xia inhibiting activity |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| MA53496A (fr) | 2018-08-31 | 2021-12-08 | Pfizer | Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées |
| ES3039586T3 (en) | 2019-05-20 | 2025-10-22 | Pfizer | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| ES3048448T3 (en) | 2020-07-22 | 2025-12-10 | Janssen Pharmaceutica Nv | Compounds useful as factor xia inhibitors |
| US20250066337A1 (en) | 2021-08-26 | 2025-02-27 | Pfizer Inc. | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4178368A (en) * | 1971-09-30 | 1979-12-11 | Behringwerke Aktiengesellschaft | Method for the treatment of thromboembolism |
| JPS5325775A (en) * | 1976-08-24 | 1978-03-09 | Miller Fluid Power Corp | Module type fluid flow control element |
| US4082612A (en) * | 1976-09-24 | 1978-04-04 | Michael Reese Research Foundation | Plasminogen activator complex |
| NZ191320A (en) * | 1978-09-07 | 1982-09-14 | Beecham Group Ltd | In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions |
-
1980
- 1980-10-27 DE DE8080303797T patent/DE3065190D1/de not_active Expired
- 1980-10-27 EP EP80303797A patent/EP0028489B1/en not_active Expired
- 1980-10-29 ZA ZA00806641A patent/ZA806641B/xx unknown
- 1980-11-03 GR GR63267A patent/GR72121B/el unknown
- 1980-11-04 DK DK468880A patent/DK158994C/da not_active IP Right Cessation
- 1980-11-04 NO NO803304A patent/NO163867C/no unknown
- 1980-11-04 CA CA000363957A patent/CA1174621A/en not_active Expired
- 1980-11-04 IL IL61408A patent/IL61408A/xx not_active IP Right Cessation
- 1980-11-04 IE IE2277/80A patent/IE50174B1/en not_active IP Right Cessation
- 1980-11-04 AR AR283122A patent/AR224786A1/es active
- 1980-11-05 NZ NZ195469A patent/NZ195469A/en unknown
- 1980-11-05 ES ES496586A patent/ES496586A0/es active Granted
- 1980-11-05 HU HU802661A patent/HU185223B/hu not_active IP Right Cessation
- 1980-11-05 JP JP15573380A patent/JPS5678590A/ja active Granted
-
1986
- 1986-08-29 US US06/902,429 patent/US4808405A/en not_active Expired - Lifetime
- 1986-09-04 HK HK658/86A patent/HK65886A/en not_active IP Right Cessation
-
1991
- 1991-12-19 CS CS913919A patent/CS391991A3/cs unknown
- 1991-12-19 CS CS913911A patent/CS391191A3/cs unknown
-
1993
- 1993-04-22 NL NL930029C patent/NL930029I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK65886A (en) | 1986-09-12 |
| DK158994B (da) | 1990-08-13 |
| AR224786A1 (es) | 1982-01-15 |
| IE50174B1 (en) | 1986-02-19 |
| DK158994C (da) | 1991-01-07 |
| IL61408A (en) | 1983-10-31 |
| NO803304L (no) | 1981-05-06 |
| GR72121B (show.php) | 1983-09-16 |
| NO163867B (no) | 1990-04-23 |
| JPH0316114B2 (show.php) | 1991-03-04 |
| JPS5678590A (en) | 1981-06-27 |
| DE3065190D1 (en) | 1983-11-10 |
| EP0028489B1 (en) | 1983-10-05 |
| ES8204467A1 (es) | 1982-05-01 |
| AU6401180A (en) | 1981-05-14 |
| NL930029I1 (nl) | 1993-06-01 |
| NO163867C (no) | 1990-08-01 |
| ES496586A0 (es) | 1982-05-01 |
| IE802277L (en) | 1981-05-05 |
| CS391991A3 (en) | 1992-06-17 |
| IL61408A0 (en) | 1980-12-31 |
| ZA806641B (en) | 1981-10-28 |
| CA1174621A (en) | 1984-09-18 |
| DK468880A (da) | 1981-05-06 |
| NZ195469A (en) | 1984-05-31 |
| NL930029I2 (nl) | 1993-12-01 |
| CS391191A3 (en) | 1992-08-12 |
| US4808405A (en) | 1989-02-28 |
| AU534017B2 (en) | 1983-12-22 |
| EP0028489A1 (en) | 1981-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU185223B (en) | Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen | |
| EP1232251B2 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| KR970005837B1 (ko) | 조직 플라스미노겐 활성화제(t-PA) 활성을 갖는 고농도 단백질 용액의 제조방법, t-PA 활성을 갖는 단백질 용액, 및 이러한 용액을 포함하는 섬유소 용해성 조성물 | |
| US6964764B2 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| HU182458B (en) | Process for preparing enzyme derivatives with in vivo fibrinolytic activity | |
| JPH0525470B2 (show.php) | ||
| Smith et al. | Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis | |
| EP1459738B1 (en) | Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties | |
| JPH01193229A (ja) | 抗血液凝固剤 | |
| JPH0672105B2 (ja) | 血栓溶解剤及びその製法 | |
| Novokhatny et al. | Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis | |
| CA2101614A1 (en) | Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them | |
| US6969515B2 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| JPH0567278B2 (show.php) | ||
| US4507283A (en) | Pharmacologically active compounds | |
| JP2002530353A (ja) | ウイルス性出血熱の処置法 | |
| NZ227183A (en) | A pharmaceutical composition comprising an aqueous hydrogel based on hydroxyethylcellulose and t-pa and/or rt-pa | |
| EP0099126B1 (en) | Thrombolytic composition | |
| JPS62153224A (ja) | プラスミノゲン製剤 | |
| JPH0369332B2 (show.php) | ||
| JPH0769921A (ja) | 網膜血管閉塞症予防治療剤 | |
| WO2012070966A1 (ru) | Модифицированные олигопептиды для лечения панкреатитов, язвенной болезни желудка и других гиперферментемий на основе пептидного ингибитора ферментов и способ их получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HPC4 | Succession in title of patentee |
Owner name: ROBERTS LABORATORIES INC. MERIDIAN CENTER II, US |
|
| HMM4 | Cancellation of final prot. due to non-payment of fee |